ArticleScientific reports2025
Global temporal trends in maternal hypertensive disorders incidence and mortality from 1990 to 2021 based on the global burden of disease study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preeclampsia Among Pregnant Women Admitted to a Tertiary Care Hospital in Taiz City: Insights from a Conflict-Stricken Setting in Southwest Yemen.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal hypertensive disorders (MHD) remain a significant global health challenge. This study aims to provide a comprehensive analysis of the global burden of MHD from 1990 to 2021, focusing on incidence and mortality trends across different sociodemographic index (SDI) regions and age groups. We utilized Global Burden of Disease (GBD) study methodologies to analyze MHD incidence and mortality. Temporal trends were examined using Joinpoint regression to calculate annual percentage changes and average annual percentage changes with 95% confidence interval (CI). Age-period-cohort models were applied to analyze trends across different age groups, time periods, and birth cohorts, with particular attention to SDI regions. Globally, the age-standardized incidence rate (ASIR) of MHD decreased from 554.35 (95% Uncertainty Interval [UI]: 461.38t o 675.43) per 100,000 in 1990 to 461.94 (95% UI: 392.73 to 551.65) in 2021, with an average annual percent change (AAPC) of - 0.6% (95% CI: -0.67% to - 0.53%). The age-standardized death rate (ASDR) declined from 1.94 (95% UI: 1.71-2.15) per 100,000 in 1990 to 0.97 (95% UI: 0.81-1.18) in 2021 (AAPC - 2.18%; 95% CI: -2.3% to - 2.06%). Low SDI regions faced the highest burden. Age-period-cohort analyses revealed heterogeneous trends across age groups and SDI regions, with younger age groups (particularly ages 15-19 years) showing the most substantial improvements, demonstrated by the steepest declines in both incidence (-1.62% per year) and mortality rates (-2.57% per year). More recent birth cohorts demonstrated greater improvements, with declining risks of both incidence and mortality compared to earlier birth cohorts. Despite global reductions in MHD incidence and mortality over the past three decades, substantial disparities persist across regions and age groups. Targeted interventions, particularly in low SDI regions and among high-risk age groups, are crucial for further reducing the global burden of MHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.